Brickhouse, A., Vredenburgh, J. J., Gururangan, S., Reardon, D. A., Desjardins, A., Peters, K., … Friedman, H. S. (2010). Phase I trial of vandetanib and oral etoposide (VP-16) for recurrent malignant gliomas (MG). Journal of Clinical Oncology, 28(15_suppl), 2038–2038. https://doi.org/10.1200/jco.2010.28.15_suppl.2038

Brickhouse, A., J. J. Vredenburgh, S. Gururangan, D. A. Reardon, A. Desjardins, K. Peters, J. E. Herndon, J. Norfleet, J. Marcello, and H. S. Friedman. “Phase I trial of vandetanib and oral etoposide (VP-16) for recurrent malignant gliomas (MG).” Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): 2038–2038. https://doi.org/10.1200/jco.2010.28.15_suppl.2038.

Brickhouse A, Vredenburgh JJ, Gururangan S, Reardon DA, Desjardins A, Peters K, et al. Phase I trial of vandetanib and oral etoposide (VP-16) for recurrent malignant gliomas (MG). Journal of Clinical Oncology. 2010 May 20;28(15_suppl):2038–2038.

Brickhouse, A., et al. “Phase I trial of vandetanib and oral etoposide (VP-16) for recurrent malignant gliomas (MG).” Journal of Clinical Oncology, vol. 28, no. 15_suppl, American Society of Clinical Oncology (ASCO), May 2010, pp. 2038–2038. Crossref, doi:10.1200/jco.2010.28.15_suppl.2038.

Brickhouse A, Vredenburgh JJ, Gururangan S, Reardon DA, Desjardins A, Peters K, Herndon JE, Norfleet J, Marcello J, Friedman HS. Phase I trial of vandetanib and oral etoposide (VP-16) for recurrent malignant gliomas (MG). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010 May 20;28(15_suppl):2038–2038.